Get the Stockscreener App
52.84
4.26%
2.16
Pre-market:
53.30
0.46
+0.87%
Moderna Inc stock is traded at $52.84, with a volume of 5.35M.
It is up +4.26% in the last 24 hours and up +0.53% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$50.68
Open:
$50.59
24h Volume:
5.35M
Relative Volume:
0.52
Market Cap:
$20.96B
Revenue:
$1.94B
Net Income/Loss:
$-2.82B
P/E Ratio:
-7.2765
EPS:
-7.2617
Net Cash Flow:
$-2.08B
1W Performance:
+5.45%
1M Performance:
+0.53%
6M Performance:
+101.30%
1Y Performance:
+97.16%
1-Day Range:
$50.05
$53.00
1-Week Range:
$50.02
$53.00
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
52.84 | 20.21B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Stock: The Case For Staying On The Sidelines (NASDAQ:MRNA) - Seeking Alpha
Moderna Inc. stock (US60770K1034): Is its mRNA platform strong enough to unlock new upside? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Pivot to Cancer Vaccines Reshapes Future - AD HOC NEWS
Moderna Inc. stock (US60770K1034): Is mRNA pipeline expansion strong enough to unlock new upside? - AD HOC NEWS
3 Unpopular Stocks We Approach with Caution - The Globe and Mail
MRNA SEC FilingsModerna 10-K, 10-Q, 8-K Forms - Stock Titan
Moderna Inc. stock (US60770K1034): Is the pivot beyond COVID vaccines now the real test? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Respiratory Vaccine Pivot Could Reshape mRNA Future - AD HOC NEWS
Moderna (MRNA) Sees Positive Momentum with Earnings Ahead - GuruFocus
Moderna Impfstoff (Spikevax): mRNA Pivot Beyond COVID Fuels Uncertain Path - AD HOC NEWS
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Milwaukee Journal Sentinel
Baillie Gifford & Co. Sells 1,266,152 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) Opinions on FDA Flu Vaccine Review - Quiver Quantitative
Best Biotech Stocks To Keep An Eye OnApril 12th - MarketBeat
Segovias de Estelí Returns to Germany via Tradición Moderna, Announces InterTabac Exclusive Release - halfwheel
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
What is behind Moderna stock's recent drop in value today - Traders Union
Moderna Inc (MRNA) Stock Price Quote Today & Current Price Chart - Capital.com
MODERNA, INC. (MRNA) - MSN
Moderna (MRNA) Experiences Bullish Trading Activity - GuruFocus
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension - Yahoo Finance
Looks Like M&A Week in 3 Different Sectors - The Motley Fool
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? - Yahoo Finance
Moderna eyes international markets as growth driver, says Bank of America - Proactive financial news
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance UK
(MRNA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Messenger RNA (mRNA) Market Projected to Reach $20.99 - GlobeNewswire
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas - Yahoo Finance
Moderna stock consolidates as short-term sellers dominate near $53.35 resistance - Traders Union
RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating - marketscreener.com
Spikevax Vaccine: Key Role in mRNA COVID Protection - AD HOC NEWS
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 - Investing News Network
New Moderna data tests repeat flu and RSV shots in older adults - Stock Titan
Moderna (MRNA) CFO vests RSUs, 703 shares withheld for tax - Stock Titan
Moderna: Speculative Buy For Aggressive Investors Betting On mRNA's Future (NASDAQ:MRNA) - Seeking Alpha
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes - Insider Monkey
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump - Yahoo Finance
Moderna Inc (MRNA) - MSN
Top Moderna Shareholders - Investopedia
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Moderna (MRNA) stock dips while market gains: Key facts - MSN
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Dayton Daily News
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna (NASDAQ:MRNA) Target Update Sparks Nasdaq 100 Index Focus - Kalkine Media
Barclays Analyst Raises Price Target for Moderna (MRNA) to $48.0 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $48.00 at Barclays - MarketBeat
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment - BioSpace
Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Moderna, Inc. Trade Ideas — BSESOF:0QF - TradingView
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):